Demand for healthcare services is unprecedented. Society is struggling to afford the cost. Pricing of biopharmaceutical products is under scrutiny, especially by payers and Health Technology Assessment agencies. As we discuss here, rapidly advancing technologies, such as Real-World Data (RWD), are being utilized to increase understanding of disease. RWD, when captured and analyzed, produces the Real-World Evidence (RWE) that underpins the economic case for innovative medicines. Furthermore, RWD can inform the understanding of disease, help identify new therapeutic intervention points, and improve the efficiency of research and development (R&D), especially clinical trials. Pursuing precompetitive collaborations to define shared requirements for the use of RWD would equip service-providers with the specifications needed to implement cloud-based solutions for RWD acquisition, management and analysis. Only this approach would deliver cost-effective solutions to an industry-wide problem.

对医疗服务的需求是空前的。社会正在努力负担这笔费用。生物制药产品的价格正在接受审查，尤其是付款人和卫生技术评估机构。正如我们在此处讨论的那样，诸如现实世界数据（RWD）之类的快速发展的技术正在被用来增进人们对疾病的了解。当对RWD进行捕获和分析时，它会产生真实世界证据（RWE），该证据为创新药物的经济案例奠定了基础。此外，RWD可以告知人们对疾病的了解，帮助确定新的治疗干预点，并提高研发（尤其是临床试验）的效率。进行竞争前的合作以定义RWD使用的共享需求将使服务提供商具备实施基于云的解决方案以进行RWD采集，管理和分析所需的规范。只有这种方法才能为整个行业的问题提供经济有效的解决方案。